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Objectives We assessed the in vivo vascular response to a new generation of zotarolimus-eluting stents
(ZES) with prolonged drug release (Resolute ZES-SR, Medtronic Vascular, Santa Rosa, California) compared
with ZES with faster kinetics (Endeavor ZES-FR, Medtronic Vascular) by optical coherence tomography.
Background Local drug release kinetics has been implicated with antirestenosis efﬁcacy of drug-
eluting stents. However, the impact of different release kinetics on vascular response of diseased
human coronary arteries remains to be investigated.
Methods The study population consisted of 43 patients with long lesions in native coronary vessels
treated with multiple overlapping ZES. Twenty-one patients treated with ZES-SR were compared with 22
patients treated with ZES-FR from the ODESSA (Optical coherence tomography for DES SAfety) study.
The primary endpoint was in-stent neointimal hyperplasia as assessed by optical coherence tomography at
6-month follow-up. Coprimary endpoints were the percentage of uncovered and malapposed struts.
Results Strut-level median neointimal thickness was 0.11 mm (interquartile range [IQR]: 0.07 to 0.15
mm) in ZES-SR and 0.31 mm (IQR: 0.27 to 0.42 mm) in ZES-FR, respectively (p  0.001). The
6-month rate of uncovered struts per patient was 7.38% (IQR: 3.06% to 12.72%) in ZES-SR and 0.00%
(IQR: 0.00% to 0.00%) in ZES-FR (p  0.001); rate of malapposed and uncovered struts was 1.47%
(IQR: 0.32% to 4.23%) in ZES-SR and 0.00% (IQR: 0.00% to 0.00%) in ZES-FR (p  0.001).
Conclusions This study demonstrated the impact of different release kinetics on human in vivo vas-
cular response to ZES implantation. The new generation of ZES-SR compared with ZES-FR had better
suppression of the neointimal response but higher proportion of uncovered and malapposed struts
at 6-month optical coherence tomography follow-up. (Optical Coherence Tomography in Long Le-
sions [LongOCT]; NCT01133925) (J Am Coll Cardiol Intv 2011;4:778–85) © 2011 by the American
College of Cardiology Foundation
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779Drug-eluting stents (DES) significantly reduce restenosis
and the need for repeat revascularization compared with
bare-metal stents (BMS) across a broad range of patient and
lesion subsets (1). Histopathological, preclinical, and clinical
studies support significant disparities in neointimal response
and vascular healing among leading polymeric DES (2,3).
ong lesions are of particular concern, as these often require
ultiple stent implantations with more extensive vascular
njury and have been associated with increased risk of stent
hrombosis and restenosis (4).
See page 786
Zotarolimus-eluting stents (ZES) (Endeavor, Medtronic
Vascular, Santa Rosa, California) have been associated with
a more prompt, complete and homogeneous coverage,
similar to BMS, but with higher percentage of neointimal
hyperplasia (NIH) when compared with sirolimus- (SES)
and paclitaxel-eluting stents (PES) (5–9). The Resolute stent
(Medtronic Vascular) is a new generation of ZES that uses the
same metallic platform (a thin-strut, cobalt-chromium alloy
stent) and the same drug (zotarolimus) and dosage of the
Endeavor stent with a newly developed biodurable polymer
(BioLinx Polymer System). The new coating enables sustained
drug elution compared with the Endeavor stent. No study has
investigated the impacts of the 2 different release kinetics on in
vivo vascular response to ZES. Optical coherence tomography
(OCT) is able to detect subtle differences in coverage and vessel
responses to DES implantation (10–12). Therefore, we de-
signed this study to assess the in vivo, human coronary vascular
response to ZES with sustained (ZES-SR) versus faster release
kinetics (ZES-FR) in a subset of long lesions with overlapping
stents.
Methods
Study design. The study design followed the ODESSA
Optical coherence tomography for DES SAfety) trial,
hich has been reported previously (8). In the present
rospective controlled study, 21 consecutive patients with
ong lesion (20 mm) were treated with the implantation of
ultiple overlapping ZES-SR (Resolute). The ZES-SR–
reated patients were compared with the ZES-FR (En-
eavor) arm from the ODESSA trial. The study was
onducted under Good Clinical Practice conditions and in
ompliance with the Medical Device Regulations for Italy.
he Ethics Review Committee of Ospedali Riuniti di
ergamo approved the protocol; patients provided written
nformed consent before enrollment.
Drug-eluting stents. The ZES-SR is coated with a 6-m
BioLinx, a blend of 3 polymers that results in sustained drug
elution in the first 30 days (approximately 85% in 30 days
and 100% by 180 days). In contrast, the ZES-FR is coated
with a 4-m phosphorylcholine coating that results in rapid arug elution (approximately 80% in 1 week and 95% in 2
eeks). Both ZES-FR and ZES-SR are loaded with same
oncentration of zotarolimus (1.6 g/mm2 of stent surface).
Patient selection, procedure, and follow-up. The inclusion
riteria were the same as for the ODESSA trial. In brief,
ligible subjects (18 years of age) had a de novo lesion in
native coronary artery with length 20 mm, diameter
tenosis (DS) 75%, reference vessel diameter of 2.5 to 3.5
m by visual estimation, requiring percutaneous coronary
ntervention with overlapping stents. Exclusion criteria were
ngoing/recent myocardial infarction, left main disease,
revious target vessel stenting, ejection fraction 30%,
reatinine 2.5 mg/dl, no suit-
ble anatomy for OCT (ostial
esions and extreme vessel tortu-
sity), and inability to comply with
ual antiplatelet therapy and
ollow-up requirements. Intracoro-
ary nitroglycerin (200 g) was ad-
inistered before imaging proce-
ures. Aspirin (100 mg daily) was
andated per protocol for 12
onths and recommended indefi-
itely. All patients received clopi-
ogrel (75 mg) daily for a minimum
f 6 months but recommended for
2 months. Angiographic, OCT,
nd intravascular ultrasound
IVUS) follow-up were performed
months after stent implantation
nd clinical outcomes were followed
or 12 months.
Quantitative coronary angiography.
Quantitative coronary angiogra-
phy was done at baseline, after
index percutaneous coronary in-
tervention, and at follow-up.
Digital coronary angiograms
were analyzed offline by an inde-
pendent core laboratory (Car-
diovascular Imaging Core Labo-
ratory, University Hospitals Case
Medical Center, Cleveland, Ohio) using validated quantitative
methods (7).
Intravascular ultrasound. IVUS was performed after index
ercutaneous coronary intervention and at 6-month
ollow-up using the Atlantis SR Pro 40-MHz catheter
Boston Scientific, Natick, Massachusetts) and the iLab
ltrasound console (Boston Scientific). IVUS images were
ecorded with a motorized pullback at 1 mm/s throughout
he stent and at least 5 mm distal and proximal to the stent.
ll IVUS data were digitally stored for subsequent analysis.
uantitative volumetric IVUS analysis was performed using
Abbreviations
and Acronyms
AIT  abnormal intraluminal
tissue
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
DM  diabetes mellitus
DS  diameter stenosis
IQR  interquartile range
ISA  incomplete stent
apposition
IVUS  intravascular
ultrasound
NIH  neointimal hyperplasia
OCT  optical coherence
tomography
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ZES  zotarolimus-eluting
stent(s)
ZES-FR  zotarolimus-
eluting stent(s) with faster
release kinetics
ZES-SR  zotarolimus-
eluting stent(s) with
sustained release kineticsvalidated semiautomated detection algorithm (Curad,
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780version 4.32, Curad, Wijk bij Duurstede, the Netherlands)
and previously described methodology (7). The cross-
sectional areas and associated volumes were determined for
the stent, lumen, vessel, and neointimal areas. Qualitative
analysis included stent malapposition, defined as blood
speckle behind the struts, categorized as persistent, resolved,
and late acquired (7).
OCT imaging acquisition and analyses. OCT images were
obtained at 6-month follow-up according to a previously
described procedure (8). In brief, a time-domain OCT
system (M2CV OCT Imaging System, LightLab Imaging,
Westford, Massachusetts) was used, and an occlusive tech-
nique was adopted. Images were acquired with an auto-
mated pullback at a rate of 1.0 mm/s, then digitally stored
and submitted to the core laboratory for offline analysis. A
dedicated software (OCT system software B.0.1, LightLab)
was used for measurements. All cross-sectional images were
initially screened for quality assessment and excluded if
images were not suitable for analysis according to a previ-
ously described method (13). Qualitative assessment was
performed in every frame (i.e., every 0.06 mm), whereas
quantitative strut level analysis and morphometric analysis
were performed at every 10 frames (i.e., 0.6-mm intervals)
along the entire target segment. Strut-level intimal thick-
ness was determined based on automated measurements
performed from the center of the luminal surface of each
strut blooming and its distance to the lumen contour. Strut
malapposition was defined when the negative value of
strut-level intimal thickness was higher than the sum of
strut thickness plus abluminal polymer thickness, according
to the stent manufacturer’s specifications plus a compensa-
tion factor of 20 m to correct for strut blooming (8).
ualitative imaging assessment included detection of ab-
ormal intraluminal tissue (AIT), defined as any irregular
ass protruding beyond the stent strut into the lumen.
ighly reproducible measurements for strut apposition,
trut coverage, and AIT qualitative assessment using the
escribed methodology have been already reported (14).
Endpoints and data management. The primary pre-
pecified OCT endpoint was the degree of in-stent NIH at
-month follow-up. Coprimary OCT endpoints included
he proportion of uncovered and malapposed struts per
atient at 6-month follow-up. The secondary endpoint was
he percentage of cross sections where 30% of struts were
ncovered. Data on clinical outcomes included major adverse
ardiac events (a composite of cardiac death, myocardial
nfarction, and target vessel revascularization), target lesion
evascularization, and stent thrombosis as per the Academic
esearch Consortium definitions of definite/probable (15) and
ere to be evaluated at 1, 6, and 12 months.
Procedural success was defined as success stent implan-
ation (20% residual stenosis) without any in-hospital
vents.Statistical methods. The analysis sample for the primary
endpoint was the intent-to-treat population. Patient, lesion,
and procedural characteristics and event rates were analyzed
using descriptive statistics with SAS (version 9.1 or higher,
SAS Institute Inc., Cary, North Carolina) with statistical
significance at the 0.05 level. Continuous variables were
expressed as mean  SD or median (interquartile range),
nd categorical variables were expressed as counts and
ercentages. For per-patient analysis, the difference between
stent types was evaluated by nonparametric Mann-
hitney U test for continuous variables, and Fisher exact
est for categorical variables. For segmental analysis, con-
inuous variables were compared using generalized estimat-
ng equations model with exchangeable correlation structure
o account for the clustering of values within each subject,
nd generalized estimating equations model or Fisher exact
est were used for the comparison of categorical variables
etween 2 stent types or overlapping versus nonoverlapping
egment when appropriate.
esults
Patient, lesion, and procedural characteristics. Baseline clin-
ical and procedural characteristics are reported in Table 1.
The 2 groups (ZES-SR, n  21; ZES-FR, n  22) were
not significantly different from each other except with
respect to higher prevalence of diabetes mellitus in the
ZES-FR group (p  0.02). Procedural success was 95.2%
for ZES-SR and 100% for ZES-FR. All patients underwent
angiography, IVUS, and OCT imaging at 6 months suc-
cessfully and without complications.
Table 1. Clinical and Procedural Characteristics
ZES-FR
(n  22)
ZES-SR
(n  21) p Value
Men 15 (68) 15 (71) 0.62
Age, yrs 64.1 9.65 68.7 10.5 0.14
Diabetes mellitus 11 (50) 3 (14) 0.02
Hyperlipidemia 12 (54) 12 (57) 1.00
Hypertension 11 (50) 10 (48) 0.92
Prior MI 7 (32) 8 (38) 0.81
Prior PCI 5 (23) 8 (38) 0.22
Lesion treated 0.11
LAD 17 (77) 12 (57) 0.16
Cx/obtuse marginal 1 (5) 3 (14) 0.27
RCA 4 (18) 6 (29) 0.42
Stent/patient 2.5 0.7 2.5 0.6 0.98
Maximum inﬂation pressure, atm 18.3 2.3 18.0 1.6 0.72
Post-dilation performed 11 (50) 16 (76) 0.44
Values are n (%) or mean SD.
Cx  circumflex; LAD  left anterior descending artery; MI  myocardial infarction; PCI 
percutaneous coronary intervention; RCA right coronary artery; ZES-FR zotarolimus-eluting
stent(s) with faster release kinetics; ZES-SR zotarolimus-eluting stent(s) with sustained releasekinetics.
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781Quantitative coronary angiography. Angiographic assess-
ments pre-procedure, post-procedure, and at 6 months are
shown in Table 2. Pre- and post-procedural angiographic
measurements were similar for ZES-SR and ZES-FR.
However, at follow-up, in-stent late lumen loss and % DS
were significantly different between the 2 groups (late lumen
loss: 0.17 mm [interquartile range (IQR): 0.00 to 0.33 mm]
in ZES-SR vs. 0.46 mm [IQR: 0.11 to 0.62 mm] in
ZES-FR, p 0.01; 18.0% DS [11.0% to 23.0%] and 25.3%
DS [19.0% to 41.0%], p  0.01, respectively). In-stent
binary restenosis was 0% for ZES-SR and 18.2% for
ZES-FR (p  0.11).
Optical coherence tomography. Using OCT, 23,091 struts
ere analyzed. Of 2,791 frames, 392 (14.1%) were excluded
rom analysis due to: location of bifurcation level (n  196,
.0%); presence of sew-up artifact (n  15, 0.5%); strut was
ut of screen (n  71, 2.6%); or presence residual blood
(n  110, 4.0%). At 6 months, NIH was significantly lower
in the ZES-SR group than in the ZES-FR group (0.11 mm
vs. 0.31 mm, p  0.01) (Table 3). However, the median
roportion of uncovered struts per patient ranged from 0%
n the ZES-FR group to 7.4% in the ZES-SR group (p 
.01) (Fig. 1). The rate of cross sections with 30%
ncovered struts was 0.0% in the ZES-FR group versus
.4% in the ZES-SR group (p  0.01). The longitudinal
istribution of covered struts is depicted in Figure 2. Three
atients (14.3%) in the ZES-SR group had AIT related to
ncovered struts compared with none (0.0%) in the
Table 2. Core Laboratory Angiographic Assessment Through 6 Months
ZES-FR
(n  22)
ZES-SR
(n  21) p Value
Pre-procedure
RVD, mm 2.59 (2.38–3.08) 2.54 (2.13–2.74) 0.25
MLD, mm 0.65 (0.43–0.85) 1.01 (0.57–1.08) 0.17
DS, % 76.0 (65.0–82.0) 63.0 (58.0–76.0) 0.11
Lesion length, mm 34.80 (32.82–48.62) 31.72 (28.80–53.18) 0.90
Post-procedure*
In-stent MLD, mm 2.18 (1.90–2.46) 2.18 (1.95–2.43) 0.90
In-segment MLD, mm 1.87 (1.62–2.17) 1.88 (1.68–2.05) 0.87
In-segment acute gain, mm 1.19 (0.94–1.55) 0.99 (0.80–1.44) 0.38
In-stent DS, % 14.5 (10.0–24.0) 13.0 (7.0–18.0) 0.33
Stent length, mm 39.54 (31.80–47.96) 37.89 (31.46–59.61) 0.75
6 months*
In-stent MLD, mm 1.76 (1.41–1.99) 2.03 (1.84–2.37) 0.02
In-segment MLD, mm 1.70 (1.36–1.95) 1.88 (1.63–2.11) 0.09
In-stent DS, % 25.25 (19.00–41.00) 18.00 (11.00–23.00) 0.01
In-stent late loss, mm 0.46 (0.11–0.62) 0.17 (0.00–0.33) 0.01
In-stent binary
restenosis, n (%)
4 (18.18) 0 (0.00) 0.11
Values are median (interquartile range) or n (%). *In-segment analysis included the segment
covered by the stent (in-stent) plus 5-mm segments proximal and distal to the stent edge.
DS diameter stenosis; MLDminimum lumen diameter; RVD reference vessel diameter;other abbreviations as in Table 1.ES-FR group. Similar proportions of uncovered struts
ere measured by OCT at overlap compared with nonover-
apping sites in both groups (Table 4). The length of overlap
as 4.32  2.28 mm in the ZES-FR group versus 3.58 
.47 mm in the ZES-SR group (p  0.13).
Intravascular ultrasound and clinical outcomes. IVUS re-
sults are reported in Table 5. Higher percentage of IVUS-
derived net volume obstruction was also found in the
ZES-FR group compared with the ZES-SR group. Late-
acquired incomplete stent apposition (ISA) was observed in
only 1 case (4.8%) treated with ZES-SR and in 3 cases
(13.6%) treated with ZES-FR. Follow-up through 1 year
was obtained in 41 of 43 patients (95.3%). There were 2
deaths in the ZES-SR group (1 cardiac at 240 days, possible
stent thrombosis based on Academic Research Consortium
definition, and 1 of noncardiac origin). One-year major
adverse cardiac event rates were 18.2% in the ZES-FR
group, including 3 target lesion revascularizations (2
ischemic-driven and 1 angiographic-driven) and 1 myocar-
dial infarction, and in the ZES-SR group, the rate was 9.5%
(2 deaths) (p  0.41).
Discussion
This study provides the first detailed comparative analysis of in
vivo human vascular responses to DES with the same platform
and drug dosage but different drug release kinetics. The study
revealed that ZES-SR was more effective for suppressing neoin-
timal proliferation than ZES-FR was, but it resulted in signifi-
cantly higher proportion of patients, frames, and stent segments
with uncovered and malapposed struts at 6-months follow-up.
DES platforms were developed to suppress neointimal
proliferation, an exaggerated healing response common to
BMS that leads to frequent repeat procedures and negative
clinical consequences (8,11,16). The potent inhibition of
cellular proliferation promoted by DES, compared with
BMS, has also been associated with delayed vascular heal-
ing, with higher percentage of uncovered strut, and in-
creased risk of very late stent thrombosis (15,17). ZES-FR
has shown less suppression of neointima growth compared
with SES and PES (18), but potentially it has a better safety
profile (5). The OCT findings observed in different lesion
and patient cohorts confirmed that ZES-FR has a more
complete, uniform, and prompt stent coverage than SES
and PES do (6–8). To increase potency in suppressing NIH,
a second generation of ZES was designed with slower drug
release kinetics, while preserving the flexible stent platform,
drug properties, and dosage (19). The present study confirms
the greater efficacy in inhibition of neointimal proliferation of
a sustained versus a fast release of ZES, which was associated
with larger lumen area and reduced NIH across all imaging
modalities (angiography, IVUS, and OCT).
ZES-SR seems to improve ZES results even in long
lesions requiring multiple stents in overlap. We recently
u
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782demonstrated that the site of overlapping DES have greater
neointimal proliferation compared with nonoverlapping
segments across all types of DES (8). Overlapping DES
Figure 1. Distribution of Stent Strut Coverage in Patients
Distribution of percentage strut coverage measured by optical coherence tomog-
raphy at 6 months, in patients treated with zotarolimus-eluting stent with sus-
tained release kinetics (ZES-SR) (n  21) (solid bars) and zotarolimus-eluting stent
with faster release kinetics (ZES-FR) stents (n  22) (open bars). Signiﬁcant differ-
ence in distribution was detected between the 2 ZES types (p  0.001).
Table 3. Optical Coherence Tomography Findings at
Result
Analyzed frames/imaged frames per patient, %
Strut level analysis
Struts per patient, n 4
Analyzed struts/cross section, n
Uncovered struts per patient, %
Uncovered, nonmalapposed struts, %
Uncovered, malapposed struts, %
Patients with any uncovered struts
Patients with any malapposed struts
Frames with 30% uncovered stent struts, %
Maximum length of uncovered segment, mm
Maximum length of malapposed segment, mm
NIH, mm
AIT related to uncovered struts
AIT related to malapposed struts
Morphometric analysis
Stent area, mm2
Lumen area, mm2
Neointimal area, mm2
Stent volume, mm3 24
Lumen volume, mm3 15
Neointimal volume, mm3 9
Net volume obstruction (%) 3
Values are median (interquartile range) or n (%).
AIT abnormal intraluminal tissue; NA not analyzable; NIH nerhave also been associated with increased rates of repeat
revascularization at 3-year follow-up (20). The degree of
NIH response in the ZES-SR group was similar between
overlapping and nonoverlapping segments (Table 4). Inter-
estingly, this favorable result was not accompanied by higher
rate of uncovered or malapposed struts at the overlap site.
Rather, the incidence of ISA was higher in the nonoverlap-
ping ZES-SR versus overlapping segments. ISA after DES
has been linked to tissue necrosis, washout of friable
thrombus or plaque material, and positive vessel remodel-
ing. Due to the lack of OCT assessment immediately after
stent implantation, no clear mechanistic explanation of ISA
can be drawn from our study.
Conversely, in the present study, a higher proportion of
uncovered struts was found in the ZES-SR group (Fig. 1).
In addition, the frequency of analyzed frames with 30%
ncovered struts, a morphometric predictor of late stent
hrombosis in histological study (17), was significantly
igher in the ZES-SR group. A previous OCT study (21)
demonstrated a substantial decrease of the frequency of
uncovered SES struts (from 10.4% to 5.7%, p  0.01)
etween 6 and 12 months. A minimum increase of NIH in
he ZES-SR group, between 4 and 9 months, was also
ths
ES-FR
 22)
ZES-SR
(n  21) p Value
9.0–67.0) 60.0 (53.0–95.0) 0.14
53.0–589.0) 566.0 (415.0–623.0) 0.16
.82–10.66) 9.59 (8.63–10.97) 0.64
.00–0.00) 7.38 (3.06–12.72) 0.01
.00–0.00) 5.85 (2.18–8.19) 0.01
.00–0.00) 1.47 (0.32–4.23) 0.01
3.6) 19 (90.5) 0.01
.0) 18 (85.7) 0.01
.00–0.00) 6.35 (0.00–16.90) 0.01
.00–0.00) 3.91 (1.92–6.35) 0.01
.00–0.00) 1.28 (0.64–3.27) 0.01
.27–0.42) 0.11 (0.07–0.15) 0.01
.0) 3 (14.3) 0.11
.0) 0 (0.0) NA
.14–7.65) 7.23 (6.22–8.41) 0.46
.43–4.75) 6.37 (5.29–7.34) 0.01
.01–3.06) 0.86 (0.65–1.32) 0.01
96.33–285.34) 292.91 (226.66–409.23) 0.12
21.53–200.53) 269.42 (169.30–394.53) 0.01
3.39–108.89) 32.43 (25.00–70.95) 0.01
2.67–43.47) 12.49 (7.86–20.23) 0.01
l hyperplasia; other abbreviations as in Table 1.6 Mon
Z
(n
55.5 (4
93.5 (3
9.66 (7
0.00 (0
0.00 (0
0.00 (0
3 (1
0 (0
0.00 (0
0.00 (0
0.00 (0
0.31 (0
0 (0
0 (0
6.85 (6
3.91 (3
2.60 (2
8.07 (1
0.97 (1
6.28 (7
6.89 (3eported in an IVUS study (22). As a result, the 6-month
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783OCT time point selected in our study might have been too
early for judging the extent of vascular response after
ZES-SR implantation. In the ODESSA trial, ZES-FR
showed homogenous coverage in OCT compared with SES
and PES. The present study confirmed similar homogenous
coverage after ZES-FR and ZES-SR implantation (Fig. 2).
In the present study, the historical control ZES-FR had
a 50% incidence of diabetes mellitus (DM), compared with
14% in the ZES-SR group (p  0.02), with possible impact
on the observed OCT findings. Although DM resulted in a
greater amount of NIH and strut coverage in SES (23), no
significant differences were observed in strut coverage and
NIH between DM and non-DM patients in our study (strut
coverage: ZES-FR: 0% in DM vs. 0% in non-DM, p 
0.51; ZES-SR: 7.28% in DM vs. 7.70% in non-DM, p 
0.51; and NIH: ZES-FR: 0.30 mm in DM vs. 0.34 mm in
non-DM, p 0.47; ZES-SR: 0.07 mm in DM vs. 0.12 mm
in non-DM, p  0.06).
Figure 2. Longitudinal Pattern of Percent Strut Coverage in
Different ZES Types
Longitudinal pattern of percent strut coverage in ZES-SR (n  21) (solid
bars) and ZES-FR stents (n  22) (open bars) as measured by optical
coherence tomography at 6-month follow-up. Data are from 10 subseg-
ments covering the entire length of the stent. The rate of coverage among
different subsegments does not change signiﬁcantly in both ZES-FR (p 
0.54) and ZES-SR stents (p  0.32). Abbreviations as in Figure 1.
Table 4. Optical Coherence Tomography Comparing Overlap Versus Nonove
ZES-FR (n  22)
OLP
26 Segments
Non-OLP
48 Segments p Value 26
Analyzed struts/cross section 14.72 3.48 8.57 1.62 0.001 15
Strut-level NIH, mm 0.39 0.16 0.33 0.12 0.004 0
Malapposed struts, % 0.00 0.00 0.00 0.00 NA 2
Uncovered struts, % 0.03 0.16 0.04 0.19 0.859 9
Values are mean SD.OLP overlap; other abbreviations as in Tables 1 and 3.ISA has been related to late stent thrombosis observed
with DES (24). ZES-FR were not associated with late-
acquired ISA, and there was very low incidence of persistent
ISA even at 3 months after the implant, in either stable or
unstable patients (9). Minimal post-stent malapposition,
not detected on IVUS but visualized by OCT, completely
disappeared or significantly decreased in the first 6 months
after ZES-FR implantation, with a residual malapposition
area of only 0.04  0.11 mm (25). In our study, a higher
rate of ISA was observed by OCT in the ZES-SR group
compared with the ZES-FR group. However, the maxi-
mum length of malapposed segment was limited to approx-
imately 1 mm. Although a small amount of ISA does not
seem to influence clinical outcome, the higher rate of ISA
and uncovered struts observed by OCT might suggest a less
prompt and favorable vessel response to ZES-SR. In accor-
dance, a higher rate of AIT related to uncovered struts was
observed in the ZES-SR group (14.3%) compared with the
ZES-FR group (0%), although it was not statistically
significant. In a large clinical study (Resolute All-Comers
trial) that randomized patients to ZES-SR or everolimus-
eluting stents, ZES-SR was found to be as safe and effective
as everolimus-eluting stents, with low late loss, target lesion
revascularization, and similar major adverse cardiac event
rates (26). However at 12 months, the rate of definite stent
thrombosis was significantly higher in the ZES-SR group,
primarily driven by 30-day stent thrombosis.
The biocompatibility of ZES-SR polymer system was
tested in vitro and in pre-clinical models, with evidence of
low inflammatory response, similar to that observed in BMS
and ZES-FR (19). In our study, no significant enlargement
of external elastic membrane by IVUS was observed in the
ZES-SR group compared with the ZES-FR group.
Study limitations. The nonrandomized design of this study
imposes some limitations on the conclusions. The higher
incidence of diabetes in 1 of the groups may have contrib-
uted to the findings. The lack of OCT imaging immediately
after stent implantation represents an important limitation to
further evaluate the mechanisms of strut malapposition. Fi-
nally, current intravascular OCT cannot detect 15 m of
issue deposition and cannot differentiate tissue characteristics.
egments
ZES-SR (n  21)
p Value OLP
ZES-FR vs. ZES-SR
p Value Non-OLP
ZES-FR vs. ZES-SRents
Non-OLP
48 Segments p Value
.13 9.31 1.72 0.001 0.32 0.21
.06 0.12 0.07 0.497 0.001 0.001
.19 3.78 7.09 0.017 0.02 0.01
2.00 9.43 11.18 0.716 0.001 0.001rlap S
OLP
Segm
.65 3
.12 0
.01 4
.70 1
r abbre
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784Conclusions
The present study demonstrated the impact of drug release
kinetics on human coronary vessel response to DES. Al-
though 2 similar stent platform and drug concentrations
were compared, differences in drug release had profound
impacts in vessel response as detected by OCT. The new
generation of ZES-SR, Resolute, has better control of the
in-stent neointimal tissue growth but a higher proportion of
uncovered and malapposed struts at 6 months compared
with the Endeavor stent. The relationship between these
surrogate OCT imaging findings and clinical outcomes
remains to be clarified.
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